ArticleAllergy2022
Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis.
Article in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Pooled it
- Review
- Allergy to PEG (polyethylene glycol) - sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2.Human vaccines & immunotherapeutics · 2024Article
- The Role of the Basophil Activation Test in the Diagnosis of Drug-Induced Anaphylaxis.Diagnostics (Basel, Switzerland) · 2024Article
- Polyethylene glycol and immunology: aspects of allergic reactions and their mechanisms, as well as ways to prevent them in clinical practice.Immunologic research · 2024Review
- A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research.Nature nanotechnology · 2024Article
- Right Biceps Pseudo-Tumor from COVID-19 Vaccination.Vaccines · 2024Article
- Occupational anaphylaxis: A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI).Allergologie select · 2024Article
- Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): A scoping review.The journal of allergy and clinical immunology. Global · 2023Article
- Graded-dosing immunization in adults at risk for immediate-type reactions to mRNA SARS-CoV-2 vaccines.Allergology international : official journal of the Japanese Society of Allergology · 2023Article
- Polyethylene glycol/polysorbate skin testing can be useful in risk assessment and management of allergic/pseudoallergic reactions to nanolipid/adenoviral vaccines.The journal of allergy and clinical immunology. In practice · 2023Article
- The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis.The journal of allergy and clinical immunology. Global · 2023Review
- Fractionated vaccination with mRNA COVID-19 vaccine is safe for patients with polyethylene glycol allergy.Clinical and translational allergy · 2023Article
- SARS-CoV-2 and allergy - what have we learned after two and a half years?Allergologie select · 2023Review
- Anaphylactic reactions after COVID-19 vaccination in Germany.Allergologie select · 2023Article
- Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization.Frontiers in allergy · 2023Article
- Basophil Activation Test with Different Polyethylene Glycols in Patients with Suspected PEG Hypersensitivity Reactions.International journal of molecular sciences · 2022Article
- Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- PEG allergy - A COVID-19 pandemic-made problem? A German perspective.The World Allergy Organization journal · 2022Article
- Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines?Allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolyethylene glycol (PEG) may elicit anaphylaxis to COVID-19 mRNA vaccines, and guidance for patients at risk is needed.
methodsIn retrospective patients with PEG allergy collected from 2006 till 2019, clinical, skin, and basophil activation test (BAT) characteristics discriminative for PEG allergy were analyzed and compared with the literature. In 421 prospective real-life patients asking for allergy workup for COVID-19 vaccine hypersensitivity in 2020/2021, risk assessment was performed and tolerance of the recommended vaccination approach was assessed.
resultsTen patients with PEG allergy were found in the retrospective cohort. Patients reacted with immediate anaphylaxis (100%) not only to PEG-based laxatives/bowel preparations or injections, but also to cold medication, antiseptics, analgetics, or antibiotics. Skin tests ± BAT with PEG ± elicitors were positive in 10/10. Provocation tests were positive in 7/9 patients. From the prospective cohort, 370/421 patients self-reporting increased risk for vaccine allergy lacked criteria necessitating allergy workup and were recommended for routine vaccination. A total of 51/421 patients were tested, and three (6%) with PEG allergy were identified, whereas 48 patients remained negative in skin tests. Vaccination was recommended in all those patients. No hypersensitivity reactions were reported to vaccination including six PEG-allergic patients tolerating COVID-19 vaccination.
conclusionsTaking a detailed history excluded PEG allergy in most referred patients and enabled direct safe vaccination. Immediate urticaria/anaphylaxis to typical elicitors identified patients requiring PEG allergy workup. Skin tests ± BAT identified PEG allergy and helped to select the vaccine and the vaccination approach. Even PEG-allergic patients can tolerate COVID-19 vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.